Talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutations

Supporting evidence

• Evaluation report

• Draft guidance committee papers (PDF 7.25 MB)

  Published:

  21 February 2024

• Final draft guidance committee papers (PDF 2.16 MB)

  Published:

  21 February 2024